Results 41 to 50 of about 18,364 (184)

The frequency of agitation due to inappropriate use of naltrexone in addicts

Advanced Biomedical Research, 2014
Background: There is a high tendency among specialists to treat the addicts with naltrexone; withdrawal symptoms are frequent after taking naltrexone along with opioids.
Sima Siadat, Nastaran Eizadi-Mood, Ali Mohammad Sabzghabaee, Farzad Gheshlaghi, Ahmad Yaraghi   +4 more
doaj   +1 more source

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements

The Milbank Quarterly, EarlyView.
Policy Points States contract with Medicaid managed care plans to administer benefits for roughly 70 million Medicaid enrollees, yet little is known about how plan benefit policies for substance use disorder (SUD) treatment medications align with state requirements.
SAGE R. FELTUS, CHRISTINA M. ANDREWS, LAUREN PETERSON, COLLEEN M. GROGAN, AMANDA J. ABRAHAM, OLIVIA M. HINDS, MAUREEN T. STEWART   +6 more
wiley   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

Substance Abuse and Rehabilitation, 2011
Paolo Mannelli, Kathleen S Peindl, Li-Tzy WuDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USAPurpose: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that ...
Peindl K, Mannelli P, Wu LT
doaj  

Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

BMC Research Notes, 2012
Background Naltrexone has been proven to be an effective treatment option for the treatment of alcohol dependency. In this article we introduce a reliable and simple method developed for the simultaneous determination of naltrexone and 6-β-naltrexol in ...
Heinälä Pekka, Lahti Tuuli, Sinclair David, Ariniemi Kari, Lillsunde Pirjo, Alho Hannu   +5 more
doaj   +1 more source

Diagnostic validity of Addictions Neuroclinical Assessment indices for alcohol use disorder: Findings from an observational case–control study

Addiction, EarlyView.
Abstract Background and aims The Addictions Neuroclinical Assessment (ANA) provides a framework for assessing alcohol use disorder (AUD) with indices that may be both mechanistically and diagnostically informative. This study evaluated an array of measures from the three ANA domains in relation to AUD diagnostic status. Design This cross‐sectional case–
Molly L. Garber, Carly McIntyre‐Wood, Mahmoud Elsayed, Michael T. Amlung, Lawrence H. Sweet, James MacKillop   +5 more
wiley   +1 more source

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide

Harm Reduction Journal, 2012
Background Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely administration of an opioid antagonist, such as naloxone or naltrexone.
Goli Veeraindar, Webster Lynn R, Lamson Michael J, Cleveland Jody M, Sommerville Kenneth W, Carter Eric   +5 more
doaj   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source